"Messy compromise" on combo SPCs in EU could increase thickets and litigation
This article was originally published in SRA
Executive Summary
More legal disputes between originators and generics companies could ensue if the Court of Justice of the European Union upholds the opinion1 of one of its advocates general on whether companies can get supplementary protection certificates on their combination drugs, according to one legal expert familiar with the case.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.